Real-World study checks safety of apixaban in the very elderly

NCT ID NCT04586972

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at nearly 1,000 people aged 80 and older with atrial fibrillation (an irregular heartbeat) who were newly prescribed the blood thinner apixaban. Researchers tracked bleeding events and how well the dose matched each patient's needs. The goal was to gather real-world safety data in this older group, who are often left out of drug trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

apixaban (a blood thinner)

What this could lead to

If successful, this study could help doctors better understand how to safely use apixaban in very elderly patients with atrial fibrillation.

What could go wrong

This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all older adults.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NONVALVULAR ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Geriatric Department, Broca Hospital

    Paris, IIe-de-France, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.